Pharmaceutical

Opinion: Pumping milk at JPM was a nightmare. It’s part...

Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry.

STAT+: Rune Labs, which makes an app to track Parkinson...

Rune Labs today announced it raised $12 million in funding led by Nexus NeuroTec...

GLP-1 drugs not linked to suicidal thoughts in FDA’s ea...

As use of drugs like Ozempic and Zepbound rises, agencies have yet to find causa...

Listen: Live! From JPM 2024

This week on "The Readout LOUD" podcast, live from #JPM24: A spate of deals and ...

Accolade beats analyst estimates, Teladoc’s optimism, a...

In the latest edition of STAT's health tech newsletter: Accolade jumps on positi...

STAT+: Pharmalittle: We’re reading about FDA’s syphilli...

Canadian Health Minister Mark Holland says Florida's plan to import cheaper phar...

Patients’ social needs often get lost in health records...

Housing, transportation and income constraints can impact patients’ health, and ...

STAT+: Courts will decide the future of Medicare’s powe...

The timeline for all those court cases about the future of Medicare’s drug price...

3M Health receives grant to develop wound treatment sol...

3M Health Care has received a $34.2m award to improve the treatment of traumatic...

GSK’s Nucala for severe eosinophilic asthma gains appro...

GSK has gained approval from the China National Medical Products Administration ...

Myrobalan Therapeutics secures funding for CNS drug dev...

Myrobalan Therapeutics has secured $24m in a Series A funding round to develop C...

Risk adjusted net present value: What is the current va...

Oratrope is a small molecule commercialized by Lumos Pharma, with a leading Phas...

FDA approves import of French drug for syphilis amidst ...

Though not approved in the US, Laboratoires Delbert’s extencilline will be the a...

European Commission greenlights Mirati’s Krazati in KRA...

Mirati filed a marketing authorisation application to the EMA for Krazati for pa...

Eli Lilly and Innovent’s obesity drug mazdutide achieve...

Innovent has reported positive Phase III results for mazdutide, Eli Lilly’s next...

NICE expands access of Paxlovid to further 1.4 million ...

Expanded patient groups at risk of progression to severe Covid-19 will be eligib...